Sugi Predict

Sugi Predict / Compounds / SCHEMBL543378

SCHEMBL543378

SCHEMBL543378

COC(=O)c1cccc2nn(C)cc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR4A2 P43354 1/20 0.45
▸ BRD4 O60885 1/20 0.44
▸ KDM4E B2RXH2 5/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ ATM Q13315 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ TSHR P16473 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ POLQ O75417 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ CFTR P13569 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ PSMD14 O00487 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ TNKS O95271 1/20 0.40
▸ ADCY10 Q96PN6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22079488 0.82 DRD3 (0.40) BRD4KDM4EPOLQALDH1A1TNKS
SCHEMBL2011238 0.82 KDM4E (0.46) NR4A2BRD4KDM4ETSHRLMNA
SCHEMBL22723833 0.81 SYK (0.44) KDM4EGAAALDH1A1TNKS
SCHEMBL21353788 0.80 TNKS (0.44) ALDH1A1TNKS
Potassium Ion SCHEMBL23858799 0.79 TNKS (0.39) BRD4KDM4EPOLQALDH1A1MAPT
SCHEMBL31082902 0.79 MET (0.41) NR4A2BRD4KDM4EKMT2AGAA
SCHEMBL19903055 0.78 TNKS (0.38) BRD4KDM4EPOLQTNKS
SCHEMBL15687631 0.76 PARP1 (0.47) KDM4EKMT2ATSHRLMNAALDH1A1
SCHEMBL17113166 0.76 L3MBTL1 (0.44) NR4A2BRD4KDM4EKMT2AGAA
SCHEMBL25362929 0.76 KDM4E (0.44) KDM4EKMT2AATMGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115335378-B Monoacylglycerol lipase modulators 詹森药业有限公司 2025-03-04 — — CN disclosed
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 — — US disclosed
US-11891387-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2024-02-06 — — US disclosed
EP-4126860-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica NV (BE) 2023-02-08 — — EP disclosed
US-20220372030-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-11-24 — — US disclosed
CN-115335378-A Monoacylglycerol lipase modulators 詹森药业有限公司 2022-11-11 — — CN disclosed
WO-2021191359-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 — — WO disclosed
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AMGEN INC. (US) 2021-06-29 — — US disclosed
US-10906890-B2 Triazole phenyl compounds as agonists of the APJ receptor AMGEN INC. (US) 2021-02-02 — — US disclosed
EP-3541810-B1 TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR AMGEN INC (US) 2020-12-23 — — EP disclosed
US-20100216803-A1 ORNITHINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-08-26 — — US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 — — US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 — — US disclosed
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED 2010-05-27 — — US disclosed
CN-101641325-A Ornithine derivative ASTELLAS PHARMA INC JP 2010-02-03 — — CN disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 — — EP disclosed
EP-2141150-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-01-06 — — EP disclosed
EP-2141147-A1 ORNITHINE DERIVATIVE Astellas Pharma Inc. (JP) 2010-01-06 — — EP disclosed
EP-2141147-A1 ORNITHINE DERIVATIVE Astellas Pharma Inc. (JP) 2010-01-06 — — EP disclosed
CN-1110478-A Indazolesulfonylurea derivative, use thereof, and intermediate for production thereof KUMIAI CHEMICAL INDUSTRY CO (JP) 1995-10-18 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216803-A1 ORNITHINE DERIVATIVE PTGER4, OXER1, ODC1 NR4A2 147/4885BRD4 784/4885KDM4E 491/4885
US-11046680-B1 Heteroaryl-substituted triazoles as APJ receptor agonists AGTR1, AGTR2, TBXA2R NR4A2 193/4885BRD4 1116/4885KDM4E 4398/4885
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP NR4A2 1794/4885BRD4 2390/4885KDM4E 3365/4885
US-11891387-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP NR4A2 1794/4885BRD4 2390/4885KDM4E 3365/4885
US-10906890-B2 Triazole phenyl compounds as agonists of the APJ receptor AGTR1, AGTR2, TBXA2R NR4A2 239/4885BRD4 1016/4885KDM4E 4276/4885
US-20100130538-A1 BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF MTNR1A, MTNR1B, XDH NR4A2 764/4885BRD4 249/4885KDM4E 2179/4885
US-20220372030-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP NR4A2 1794/4885BRD4 2390/4885KDM4E 3365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.